Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein S6 pseudogene 26 (RPS6P26) is a genomic sequence in humans derived from the ribosomal protein S6 (RPS6) gene, but is considered a processed pseudogene and does not encode a functional protein[6][4]. Pseudogenes like RPS6P26 are formed by retrotransposition events that duplicate mRNA-derived gene sequences into new genomic locations, often leading to loss of coding potential due to mutations or truncations[4]. RPS6P26, like most pseudogenes, does not have known biological activity, is not associated with any disease state, and is not a target for any currently known drugs. While the functional RPS6 gene plays a role in ribosome structure and function, RPS6P26 simply serves as a non-functional genomic relic with no direct role in cellular physiology or as a therapeutic target[6][4]. If you need information on the parent gene (RPS6), which is functionally active and biologically relevant, please specify.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S6 pseudogene 26 (RPS6P26).